Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 1.00 |
| ▸ | ITGAV | P06756 | 19/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 8/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.64 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.64 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30856550 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL979390 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL243383 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL12948919 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL30856556 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL12922973 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL2043371 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL6419346 | 0.90 | ITGB3 (0.82) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL6423290 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL12010935 | 0.90 | ITGB3 (0.81) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257538-B1 | Process for the preparation of benzodiazepine derivatives | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | claimed |
| US-8076475-B2 | Process | GLAXOSMITHKLINE LLC (US) | 2011-12-13 | — | — | US | claimed |
| US-20110015390-A1 | PROCESS | GLAXOSMITHKLINE LLC | 2011-01-20 | — | — | US | claimed |
| EP-2257538-A2 | PROCESS | GlaxoSmithKline LLC (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009111679-A2 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | claimed |
| EP-0957917-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | claimed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | claimed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | claimed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | claimed |
| WO-2024024915-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PERIOSTIN-MEDIATED DISEASE AND PRURITUS ASSOCIATED THEREWITH | 国立大学法人佐賀大学 | 2024-02-01 | — | — | WO | disclosed |
| EP-2257538-B1 | Process for the preparation of benzodiazepine derivatives | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8076475-B2 | Process | GLAXOSMITHKLINE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076475-B2 | Process | GLAXOSMITHKLINE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20030125317-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-07-03 | — | — | US | disclosed |
| EP-0957917-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
| US-20110015390-A1 | PROCESS | PTAFR, HCAR2, GPR142 | ITGB3 173/4885ITGAV 200/4885ITGA2B 182/4885 |
| US-20030125317-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.